NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $11.65 +0.10 (+0.87%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$11.78 +0.13 (+1.07%) As of 04/25/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evolus Stock (NASDAQ:EOLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evolus alerts:Sign Up Key Stats Today's Range$11.24▼$11.9650-Day Range$9.36▼$14.8852-Week Range$8.67▼$17.82Volume800,262 shsAverage Volume668,010 shsMarket Capitalization$740.79 millionP/E RatioN/ADividend YieldN/APrice Target$23.75Consensus RatingBuy Company OverviewEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More… Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 75% of companies evaluated by MarketBeat, and ranked 231st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 4 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -12.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evolus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.03% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Evolus has recently increased by 1.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.27 Percentage of Shares Shorted12.03% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Evolus has recently increased by 1.42%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.94 News SentimentEvolus has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Evolus this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $794,369.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Stock News HeadlinesEvolus: Two-Product Aesthetics Company With A Competitive EdgeApril 22, 2025 | seekingalpha.comEvolus (NASDAQ:EOLS) Earns Buy Rating from Analysts at BTIG ResearchApril 20, 2025 | americanbankingnews.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 26, 2025 | Porter & Company (Ad)Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2025 | businesswire.comBTIG Initiates Coverage of Evolus (EOLS) with Buy RecommendationApril 18, 2025 | msn.comEvolus initiated with a Buy at BTIGApril 17, 2025 | markets.businessinsider.comEvolus Announces Commercial Launch of Evolysse™April 17, 2025 | finance.yahoo.comEvolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid GelsApril 15, 2025 | finance.yahoo.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $11.04 on January 1st, 2025. Since then, EOLS shares have increased by 5.5% and is now trading at $11.65. View the best growth stocks for 2025 here. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) announced its earnings results on Tuesday, March, 23rd. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The company earned $20.58 million during the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 847.60% and a negative net margin of 22.33%. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Top institutional investors of Evolus include Assenagon Asset Management S.A. (1.12%), Rhumbline Advisers (0.13%) and GAMMA Investing LLC (0.03%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, David N Gill and Robert Hayman. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings3/23/2021Today4/25/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$23.75 High Stock Price Target$27.00 Low Stock Price Target$21.00 Potential Upside/Downside+103.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-22.33% Pretax Margin-22.20% Return on Equity-847.60% Return on Assets-22.15% Debt Debt-to-Equity Ratio20.58 Current Ratio2.47 Quick Ratio2.23 Sales & Book Value Annual Sales$266.27 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-32.36Miscellaneous Outstanding Shares63,587,000Free Float59,458,000Market Cap$740.79 million OptionableOptionable Beta0.97 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EOLS) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.